REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Paediatric > Paediatric Chapters > 6. Endocrine system >

BNSSG Paediatric Joint Formulary

6.9 Obesity

Last edited: 07-10-2025

6.9 Obesity

First line drugs Second line drugs Specialist drugs Secondary care drugs

 

Orlistat (TLS Red)

  • Unlicensed

Semaglutide (Wegovy) for severe obesity in children (TLS Red) 

  • Approved for children and young people between 12 and 18 years of age with severe obesity as an option for weight management as an adjuvant to lifestyle modification
  • Use is via Prior Approval Scheme as per the criteria on Blueteq